Suppr超能文献

种族差异与临床显著前列腺癌治疗:潜在的健康信息技术应用。

Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.

机构信息

Icahn School of Medicine at Mount Sinai; Columbia University College of Physicians and Surgeons, New York, NY; and The Ohio State University, Columbus, OH.

出版信息

J Oncol Pract. 2018 Jan;14(1):e23-e33. doi: 10.1200/JOP.2017.025957. Epub 2017 Dec 1.

Abstract

PURPOSE

Black men are more likely to die as a result of prostate cancer than white men, despite effective treatments that improve survival for clinically significant prostate cancer. We undertook this study to identify gaps in prostate cancer care quality, racial disparities in care, and underlying reasons for poorer quality care.

METHODS

We identified all black men and random age-matched white men with Gleason scores ≥ 7 diagnosed between 2006 and 2013 at two urban hospitals to determine rates of treatment underuse. Underuse was defined as not receiving primary surgery, cryotherapy, or radiotherapy. We then interviewed treating physicians about the reasons for underuse.

RESULTS

Of 359 black and 282 white men, only 25 (4%) experienced treatment underuse, and 23 (92%) of these were black. Most (78%) cases of underuse were due to system failures, where treatment was recommended but not received; 38% of these men continued receiving care at the hospitals. All men with treatment underuse due to system failures were black.

CONCLUSION

Treatment rates of prostate cancer are high. Yet, racial disparities in rates and causes of underuse remain. Only black men experienced system failures, a type of underuse amenable to health information technology-based solutions. Institutions are missing opportunities to use their health information technology capabilities to reduce disparities in cancer care.

摘要

目的

尽管有效的治疗方法可以提高临床显著前列腺癌的生存率,但黑人男性死于前列腺癌的可能性仍然高于白人男性。我们进行这项研究是为了确定前列腺癌护理质量差距、护理中的种族差异以及护理质量较差的根本原因。

方法

我们在两家城市医院确定了所有在 2006 年至 2013 年间诊断为 Gleason 评分≥7 的黑人男性和随机年龄匹配的白人男性,以确定治疗不足的发生率。治疗不足被定义为未接受主要手术、冷冻疗法或放射疗法。然后,我们采访了主治医生,了解治疗不足的原因。

结果

在 359 名黑人男性和 282 名白人男性中,只有 25 名(4%)经历了治疗不足,其中 23 名(92%)为黑人。大多数(78%)治疗不足的病例是由于系统故障导致的,即建议但未接受治疗;其中 38%的患者继续在医院接受治疗。所有因系统故障而治疗不足的男性均为黑人。

结论

前列腺癌的治疗率很高。然而,治疗不足的发生率和原因仍然存在种族差异。只有黑人男性经历了系统故障,这是一种可以通过基于健康信息技术的解决方案来解决的治疗不足类型。医疗机构错过了利用其健康信息技术能力来减少癌症护理中的差异的机会。

相似文献

1
Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.
J Oncol Pract. 2018 Jan;14(1):e23-e33. doi: 10.1200/JOP.2017.025957. Epub 2017 Dec 1.
2
Hospital racial composition and the treatment of localized prostate cancer.
Cancer. 2011 Dec 15;117(24):5569-78. doi: 10.1002/cncr.26232. Epub 2011 Jun 20.
3
A multidimensional view of racial differences in access to prostate cancer care.
Cancer. 2017 Nov 15;123(22):4449-4457. doi: 10.1002/cncr.30894. Epub 2017 Jul 20.
4
A tracking and feedback registry to reduce racial disparities in breast cancer care.
J Natl Cancer Inst. 2008 Dec 3;100(23):1717-23. doi: 10.1093/jnci/djn387. Epub 2008 Nov 25.
7
Factors influencing prostate cancer treatment decisions for African American and white men.
Cancer. 2019 May 15;125(10):1693-1700. doi: 10.1002/cncr.31932. Epub 2019 Jan 29.
9
Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.
Cancer. 2023 May 1;129(9):1402-1410. doi: 10.1002/cncr.34681. Epub 2023 Feb 13.
10
Racial Differences in Treatment Decision-Making for Men with Clinically Localized Prostate Cancer: a Population-Based Study.
J Racial Ethn Health Disparities. 2016 Mar;3(1):35-45. doi: 10.1007/s40615-015-0109-8. Epub 2015 May 5.

引用本文的文献

1
Ethnic differences in prostate cancer presentation: a time for testing advocacy.
World J Urol. 2023 Dec;41(12):3543-3549. doi: 10.1007/s00345-023-04644-0. Epub 2023 Oct 11.
2
Racial disparities in Black men with prostate cancer: A literature review.
Cancer. 2022 Nov 1;128(21):3787-3795. doi: 10.1002/cncr.34433. Epub 2022 Sep 6.
3
Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.
World J Mens Health. 2022 Apr;40(2):217-227. doi: 10.5534/wjmh.210070. Epub 2022 Jan 1.
4
Pathogenic Variants as Biomarkers for Risk in Prostate Cancer.
Cancers (Basel). 2021 Nov 14;13(22):5697. doi: 10.3390/cancers13225697.

本文引用的文献

1
Comparing Prostate Cancer Treatment Decision Making in a Resource-rich and a Resource-poor Environment: A Tale of two Hospitals.
J Natl Med Assoc. 2016 Winter;108(4):211-219. doi: 10.1016/j.jnma.2016.08.002. Epub 2016 Sep 15.
2
United States Health Care Reform: Progress to Date and Next Steps.
JAMA. 2016 Aug 2;316(5):525-32. doi: 10.1001/jama.2016.9797.
3
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer.
JAMA Oncol. 2016 Jan;2(1):85-93. doi: 10.1001/jamaoncol.2015.3384.
4
Lessons From Early Implementation of a Patient-Centered Care Model in Oncology.
J Oncol Pract. 2015 Nov;11(6):456-61. doi: 10.1200/JOP.2015.006072. Epub 2015 Sep 29.
9
Racial variation in the quality of surgical care for prostate cancer.
J Urol. 2012 Oct;188(4):1279-85. doi: 10.1016/j.juro.2012.06.037. Epub 2012 Aug 16.
10
Radical prostatectomy versus observation for localized prostate cancer.
N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验